Handelsavisen
prelaunch
Companies Healthcare 1931.HK
19
1931.HK HKEX Medical Equipment, Supplies & Distribution

Ethk Labs Inc

HK$0,86
Open in Charts → Attach watcher ⌖
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
6,4 %
ROE
1,2 %
Net margin
1,2 %
Debt / equity
0,62
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Ethk Labs Inc maintains a capital structure with a debt-to-equity ratio of 0.62, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is characterized by a current ratio of 1.34, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's cash and equivalents of CNY 350.92 million are significantly lower than its long-term debt of CNY 1.84 billion, resulting in a net cash position that is negative after subtracting total debt. In terms of profitability, Ethk Labs Inc reports a return on equity (ROE) of 1.19% and a return on assets (ROA) of 0.59%. These figures are below the industry median for ROE and ROA in the Medical Equipment, Supplies & Distribution sector, indicating that the company is underperforming in terms of generating returns relative to its equity and asset base. The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no material geographic diversification provided in the available data. This lack of segmental or geographic diversification may expose the company to higher operational and market risks, particularly in the ev

Business. Ethk Labs Inc (1931.HK) is a healthcare services and equipment company primarily engaged in the medical equipment, supplies, and distribution industry. The firm operates on a product-sale revenue model, focusing on the provision of medical devices and related supplies. Ethk Labs is listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic presence are not disclosed in the available data.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
1,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 1931.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 1931.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Ethk Labs Inc (1931.HK) is a healthcare services and equipment company primarily engaged in the medical equipment, supplies, and distribution industry. The firm operates on a product-sale revenue model, focusing on the provision of medical devices and related supplies. Ethk Labs is listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic presence are not disclosed in the available data.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    Ethk Labs Inc maintains a capital structure with a debt-to-equity ratio of 0.62, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is characterized by a current ratio of 1.34, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's cash and equivalents of CNY 350.92 million are significantly lower than its long-term debt of CNY 1.84 billion, resulting in a net cash position that is negative after subtracting total debt.

    In terms of profitability, Ethk Labs Inc reports a return on equity (ROE) of 1.19% and a return on assets (ROA) of 0.59%. These figures are below the industry median for ROE and ROA in the Medical Equipment, Supplies & Distribution sector, indicating that the company is underperforming in terms of generating returns relative to its equity and asset base.

    The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no material geographic diversification provided in the available data. This lack of segmental or geographic diversification may expose the company to higher operational and market risks, particularly in the event of a downturn in its primary market.

    Looking ahead, Ethk Labs Inc is projected to experience a modest growth trajectory, with the outlook for the current fiscal year and the next fiscal year not showing significant revenue growth. The company's historical revenue of CNY 2.82 billion provides a baseline for future performance, but the absence of a clear growth driver or expansion strategy may limit its ability to scale.

    The company faces several risk factors, including a medium liquidity risk due to its current ratio and a negative net cash position. Additionally, the risk of dilution is assessed as low, with no immediate pressure for share issuance. However, the company's reliance on long-term debt and the absence of a strong equity cushion may pose challenges in maintaining financial flexibility.

    Recent events, including filings and transcripts, have not revealed any material changes in the company's operations or strategic direction. The company continues to operate within its core business of medical equipment and supplies, with no significant new product launches or market expansions disclosed in the latest available data.

    Key takeaways
    • Ethk Labs Inc has a moderate debt-to-equity ratio of 0.62, indicating a balanced capital structure but with room for improvement in equity generation.
    • The company's ROE of 1.19% and ROA of 0.59% are below industry medians, suggesting underperformance in profitability.
    • Ethk Labs Inc lacks geographic and segmental diversification, increasing its exposure to market-specific risks.
    • The company's liquidity position is medium, with a current ratio of 1.34, but its net cash position is negative after subtracting total debt.
    • No significant growth drivers or strategic initiatives have been disclosed, which may limit the company's ability to scale in the near term.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    HK$0,86
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    HK$2.95B
    Net cash
    -HK$1.49B
    Current ratio
    1.3
    Debt / equity
    0.6
    ROA
    0.6%
    ROE
    1.2%
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin6,4 %Above median
    Net Margin1,2 %Below median
    ROE1,2 %Below median
    D/E0,62Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Return On Assets
      net_income / total_assets
    Source documents
    • Ethk Labs Inc Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    1931.HKCanonical
    HKEX · HKD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage